• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Effect of Tumor Size and Histologic Findings on Outcomes After Segmentectomy vs Lobectomy for Clinically Node-Negative Non-Small Cell Lung Cancer.肿瘤大小和组织学发现对临床淋巴结阴性非小细胞肺癌行解剖性肺段切除术与肺叶切除术术后结局的影响。
Chest. 2021 Jan;159(1):390-400. doi: 10.1016/j.chest.2020.06.066. Epub 2020 Jul 8.
2
Survival Rates After Lobectomy, Segmentectomy, and Wedge Resection for Non-Small Cell Lung Cancer.非小细胞肺癌行肺叶切除术、节段切除术和楔形切除术的生存率。
Ann Thorac Surg. 2018 May;105(5):1483-1491. doi: 10.1016/j.athoracsur.2018.01.032. Epub 2018 Feb 17.
3
Choice of Surgical Procedure for Patients With Non-Small-Cell Lung Cancer ≤ 1 cm or > 1 to 2 cm Among Lobectomy, Segmentectomy, and Wedge Resection: A Population-Based Study.≤1 厘米或>1 至 2 厘米的非小细胞肺癌患者的手术方式选择:肺叶切除术、节段切除术和楔形切除术:一项基于人群的研究。
J Clin Oncol. 2016 Sep 10;34(26):3175-82. doi: 10.1200/JCO.2015.64.6729. Epub 2016 Jul 5.
4
Impact of tumor size on outcomes after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system.基于现行分期系统,肿瘤大小对 1A 期非小细胞肺癌解剖性肺切除术后结局的影响。
J Thorac Cardiovasc Surg. 2012 Feb;143(2):390-7. doi: 10.1016/j.jtcvs.2011.10.023. Epub 2011 Dec 9.
5
Survival after lobectomy versus segmentectomy for stage I non-small cell lung cancer: a population-based analysis.肺叶切除术与节段切除术治疗 I 期非小细胞肺癌的生存比较:一项基于人群的分析。
Ann Thorac Surg. 2011 Dec;92(6):1943-50. doi: 10.1016/j.athoracsur.2011.05.091. Epub 2011 Oct 1.
6
Node-Positive Segmentectomy for Non-Small-Cell Lung Cancer: Risk Factors and Outcomes.非小细胞肺癌的阳性结节段切除术:危险因素与结果。
Clin Lung Cancer. 2019 Jul;20(4):e463-e469. doi: 10.1016/j.cllc.2019.03.006. Epub 2019 Apr 1.
7
Long-Term Results for Clinical Stage IA Lung Cancer: Comparing Lobectomy and Sublobar Resection.临床ⅠA 期肺癌的长期结果:肺叶切除术与亚肺叶切除术比较。
Ann Thorac Surg. 2018 Aug;106(2):375-381. doi: 10.1016/j.athoracsur.2018.02.049. Epub 2018 Mar 23.
8
Rationale for a Minimum Number of Lymph Nodes Removed with Non-Small Cell Lung Cancer Resection: Correlating the Number of Nodes Removed with Survival in 98,970 Patients.非小细胞肺癌切除术中清扫淋巴结最少数量的理论依据:98970例患者清扫淋巴结数量与生存情况的相关性
Ann Surg Oncol. 2016 Dec;23(Suppl 5):1005-1011. doi: 10.1245/s10434-016-5509-4. Epub 2016 Aug 16.
9
Segmentectomy versus lobectomy in early non-small cell lung cancer of 2 cm or less in size: A population-based study.肺段切除术与肺叶切除术治疗 2cm 或以下早期非小细胞肺癌的对比:一项基于人群的研究。
Respirology. 2018 Jul;23(7):695-703. doi: 10.1111/resp.13277. Epub 2018 Feb 21.
10
Lobectomy does not confer survival advantage over segmentectomy for non-small cell lung cancer with unsuspected nodal disease.肺叶切除术并不比节段切除术更能为伴有隐匿性淋巴结疾病的非小细胞肺癌患者带来生存优势。
J Thorac Cardiovasc Surg. 2020 Jun;159(6):2469-2483.e4. doi: 10.1016/j.jtcvs.2019.10.165. Epub 2019 Nov 21.

引用本文的文献

1
Advances in molecular pathology and therapy of non-small cell lung cancer.非小细胞肺癌分子病理学与治疗的进展
Signal Transduct Target Ther. 2025 Jun 15;10(1):186. doi: 10.1038/s41392-025-02243-6.
2
Temporal Trends in the Utilization and Survival Outcomes of Lobar, Segmental, and Wedge Resection for Early-Stage NSCLC, 2004 to 2020.2004年至2020年早期非小细胞肺癌肺叶、肺段和楔形切除术的应用及生存结果的时间趋势
JTO Clin Res Rep. 2025 Jan 8;6(3):100794. doi: 10.1016/j.jtocrr.2025.100794. eCollection 2025 Mar.
3
Surgical management of stage IE/IIE primary pulmonary lymphomas: a propensity score matching study.ⅠE/ⅡE期原发性肺淋巴瘤的外科治疗:一项倾向评分匹配研究
J Thorac Dis. 2025 Jan 24;17(1):134-149. doi: 10.21037/jtd-24-1524. Epub 2025 Jan 22.
4
Insights into sex differences in perioperative outcomes of non-small cell lung cancer patients.非小细胞肺癌患者围手术期结局的性别差异洞察
Transl Lung Cancer Res. 2024 Oct 31;13(10):2549-2560. doi: 10.21037/tlcr-24-336. Epub 2024 Oct 23.
5
Stage I and II nonsmall cell lung cancer treatment options.I期和II期非小细胞肺癌的治疗选择。
Breathe (Sheff). 2024 Aug 27;20(2):230219. doi: 10.1183/20734735.0219-2023. eCollection 2024 Jun.
6
Impact of Tumor Size and Differentiation Grade on Survival After Lobectomy and Segmentectomy for Patients with Early-Stage Lung Adenocarcinoma.肿瘤大小和分化程度对早期肺腺癌患者行肺叶切除术和肺段切除术的生存影响。
Ann Surg Oncol. 2024 Dec;31(13):9289-9297. doi: 10.1245/s10434-024-15673-3. Epub 2024 Jun 27.
7
Multiplex Intraoperative Rapid Immunohistochemistry with Noncontact Antibody Mixing for Distinguishing the Histologic Phenotype of Lung Cancer.用于区分肺癌组织学表型的非接触抗体混合多重术中快速免疫组织化学
Pathobiology. 2024;91(6):383-392. doi: 10.1159/000539640. Epub 2024 Jun 24.
8
Clinical significance of postoperative folate receptor-positive circulating tumor cells (FR + CTCs) for long-term prognosis in patients with invasive adenocarcinoma (IAC) of the lung.术后叶酸受体阳性循环肿瘤细胞(FR+CTCs)对肺浸润性腺癌(IAC)患者长期预后的临床意义。
Thorac Cancer. 2024 May;15(13):1060-1071. doi: 10.1111/1759-7714.15288. Epub 2024 Mar 26.
9
The prognostic significance of lymph nodes in patients with pT1c33N0M0 non-small cell lung cancer: a retrospective study.pT1c33N0M0 期非小细胞肺癌患者淋巴结的预后意义:一项回顾性研究
PeerJ. 2024 Jan 31;12:e16866. doi: 10.7717/peerj.16866. eCollection 2024.
10
Usenamine A triggers NLRP3/caspase-1/GSDMD-mediated pyroptosis in lung adenocarcinoma by targeting the DDX3X/SQSTM1 axis.乌司他丁 A 通过靶向 DDX3X/SQSTM1 轴触发肺腺癌中 NLRP3/半胱天冬酶-1/GSDMD 介导的细胞焦亡。
Aging (Albany NY). 2024 Jan 23;16(2):1663-1684. doi: 10.18632/aging.205450.

本文引用的文献

1
Outcomes for Surgery in Large Cell Lung Neuroendocrine Cancer.大细胞神经内分泌肺癌的手术治疗结果。
J Thorac Oncol. 2019 Dec;14(12):2143-2151. doi: 10.1016/j.jtho.2019.09.005. Epub 2019 Sep 23.
2
Oncological Outcomes of Lobar Resection, Segmentectomy, and Wedge Resection for T1a Non-Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis.T1a 期非小细胞肺癌行肺叶切除术、节段切除术和楔形切除术的肿瘤学结果:系统评价和荟萃分析。
Semin Thorac Cardiovasc Surg. 2020;32(3):582-590. doi: 10.1053/j.semtcvs.2019.08.004. Epub 2019 Aug 9.
3
Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial.肺段切除术与肺叶切除术的比较:一项随机试验的安全性结果。
J Thorac Cardiovasc Surg. 2019 Sep;158(3):895-907. doi: 10.1016/j.jtcvs.2019.03.090. Epub 2019 Apr 9.
4
Sublobar Resection in the Treatment of Peripheral Typical Carcinoid Tumors of the Lung.亚肺叶切除术治疗周围典型类癌肺肿瘤。
Ann Thorac Surg. 2019 Sep;108(3):859-865. doi: 10.1016/j.athoracsur.2019.04.005. Epub 2019 May 3.
5
Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503).亚肺叶切除术与肺叶切除术治疗早期非小细胞肺癌的围手术期死亡率和发病率:一项国际、随机、III 期试验(CALGB/Alliance 140503)的事后分析。
Lancet Respir Med. 2018 Dec;6(12):915-924. doi: 10.1016/S2213-2600(18)30411-9. Epub 2018 Nov 12.
6
Lobectomy vs. segmentectomy. A propensity score matched comparison of outcomes.肺叶切除术与肺段切除术。一项基于倾向评分匹配的结局比较。
Eur J Surg Oncol. 2019 May;45(5):845-850. doi: 10.1016/j.ejso.2018.10.534. Epub 2018 Nov 1.
7
Segmentectomy Is Equivalent to Lobectomy in Hypermetabolic Clinical Stage IA Lung Adenocarcinomas.肺段切除术与肺叶切除术在高代谢临床ⅠA 期肺腺癌中的等效性。
Ann Thorac Surg. 2019 Jan;107(1):217-223. doi: 10.1016/j.athoracsur.2018.07.042. Epub 2018 Sep 19.
8
Sublobar resections for small-sized stage Ia lung adenocarcinoma: a Sino-Japanese multicenter study.小尺寸Ia期肺腺癌的亚肺叶切除术:一项中日多中心研究
J Thorac Dis. 2018 Feb;10(2):991-998. doi: 10.21037/jtd.2018.01.63.
9
Long-Term Results for Clinical Stage IA Lung Cancer: Comparing Lobectomy and Sublobar Resection.临床ⅠA 期肺癌的长期结果:肺叶切除术与亚肺叶切除术比较。
Ann Thorac Surg. 2018 Aug;106(2):375-381. doi: 10.1016/j.athoracsur.2018.02.049. Epub 2018 Mar 23.
10
Survival Rates After Lobectomy, Segmentectomy, and Wedge Resection for Non-Small Cell Lung Cancer.非小细胞肺癌行肺叶切除术、节段切除术和楔形切除术的生存率。
Ann Thorac Surg. 2018 May;105(5):1483-1491. doi: 10.1016/j.athoracsur.2018.01.032. Epub 2018 Feb 17.

肿瘤大小和组织学发现对临床淋巴结阴性非小细胞肺癌行解剖性肺段切除术与肺叶切除术术后结局的影响。

The Effect of Tumor Size and Histologic Findings on Outcomes After Segmentectomy vs Lobectomy for Clinically Node-Negative Non-Small Cell Lung Cancer.

机构信息

Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC.

Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC.

出版信息

Chest. 2021 Jan;159(1):390-400. doi: 10.1016/j.chest.2020.06.066. Epub 2020 Jul 8.

DOI:10.1016/j.chest.2020.06.066
PMID:32652096
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7856530/
Abstract

BACKGROUND

The interaction between tumor size and the comparative prognosis of lobar and sublobar resection has been defined poorly.

RESEARCH QUESTION

The purpose of this study was to characterize the relationship between tumor size and the receipt of segmentectomy or lobectomy in association with overall survival in patients with clinically node-negative non-small cell lung cancer (NSCLC).

STUDY DESIGN AND METHODS

The 2004-2015 National Cancer Database (NCDB) was queried for patients with cT1-3N0M0 NSCLC who underwent segmentectomy or lobectomy without neoadjuvant therapy or missing survival data. The primary outcome was overall survival, which was evaluated using multivariate Cox proportional hazards including an interaction term between tumor size and type of surgery.

RESULTS

A total of 143,040 patients were included: 135,446 (95%) underwent lobectomy and 7594 (5%) underwent segmentectomy. In multivariate Cox regression, a significant three-way interaction was found among tumor size, histologic results, and type of surgery (P < .001). When patients were stratified by histologic results, lobectomy was associated with significantly improved survival compared with segmentectomy beyond a tumor size of approximately 10 mm for adenocarcinoma and 15 mm for squamous cell carcinoma that was recapitulated in subgroup analyses. No interaction between tumor size and type of surgery was found for patients with neuroendocrine tumors.

INTERPRETATION

In this NCDB study of patients with node-negative NSCLC, we found different tumor size thresholds, based on histologic results, that identified populations of patients who least and most benefitted from lobectomy compared with segmentectomy.

摘要

背景

肿瘤大小与肺叶切除和亚肺叶切除比较预后的相互作用尚未明确。

研究问题

本研究的目的是描述肿瘤大小与临床淋巴结阴性非小细胞肺癌(NSCLC)患者接受段切或肺叶切与总生存之间的关系。

研究设计与方法

本研究通过 2004 年至 2015 年国家癌症数据库(NCDB),对未接受新辅助治疗或生存数据缺失的 cT1-3N0M0 NSCLC 患者进行了段切或肺叶切的回顾性分析。主要结局是总生存,通过多变量 Cox 比例风险模型评估,包括肿瘤大小和手术类型之间的交互项。

结果

共纳入 143040 例患者:135446 例(95%)行肺叶切除术,7594 例(5%)行段切除术。多变量 Cox 回归显示,肿瘤大小、组织学结果和手术类型之间存在显著的三向交互作用(P<.001)。当根据组织学结果对患者进行分层时,在腺癌肿瘤大小约 10mm 以上和鳞癌肿瘤大小约 15mm 以上,肺叶切除术与段切除术相比,生存获益显著,这在亚组分析中得到了验证。对于神经内分泌肿瘤患者,未发现肿瘤大小与手术类型之间存在交互作用。

解释

在这项针对淋巴结阴性 NSCLC 患者的 NCDB 研究中,我们发现,根据组织学结果,存在不同的肿瘤大小阈值,可以确定哪些患者最能从肺叶切除术和段切除术获益。